Advertisement

Topics

These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA. LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use Initial U.S. Approval: 2018 | Lutathera [Advanced Accelerator Applications USA, Inc] | BioPortfolio

13:09 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

LUTATHERA is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions ( 5.1)] . Use waterproof gloves and effective radiation shielding when handling LUTATHERA. Radiopharmaceuticals, including LUTATHERA, should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Use in Specific Populations ( 8.1, 8.3)] .

The recommended LUTATHERA dose is 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses. Administer pre- and concomitant medications and administer LUTATHERA as recommended [see Dosage and Administration ( 2.3, 2.5) ].

Somatostatin Analogs

Antiemetic Administer antiemetics 30 minutes before the recommended amino acid solution.

Amino Acid Solution Initiate an intravenous amino acid solution containing L-lysine and L-arginine (Table 1) 30 minutes before administering LUTATHERA. Use a three-way valve to administer amino acids using the same venous access as LUTATHERA or administer amino acids through a separate venous access in the patient’s other arm. Continue the infusion during, and for at least 3 hours after LUTATHERA infusion. Do not decrease the dose of the amino acid solution if the dose of LUTATHERA is reduced [see Warnings and Precautions ( 5.4)] .

Table 1. Amino Acid Solution
Item Specification
Lysine HCl content Between 18 g and 24 g
Arginine HCl content Between 18 g and 24 g
Volume 1.5 L to 2.2 L
Osmolarity < 1050 mOsmol

Recommended dose modifications of LUTATHERA for adverse reactions are provided in Table 2.

Table 2. Recommended Dose Modifications of LUTATHERA for Adverse Reactions
Adverse Reaction Severity of Adverse Reaction National Cancer Institute, Common Toxicity Criteria for Adverse Events, version 4.03 Dose Modification
Thrombocytopenia [see Warnings and Precautions (5.2)] Grade 2, 3 or 4 Withhold dose until complete or partial resolution (Grade 0 to 1).
Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3 or 4 thrombocytopenia, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue LUTATHERA for Grade 2 or higher thrombocytopenia requiring a treatment delay of 16 weeks or longer.
Recurrent Grade 2, 3 or 4 Permanently discontinue LUTATHERA.
Anemia and Neutropenia [see Warnings and Precautions (5.2)] Grade 3 or 4 Withhold dose until complete or partial resolution (Grade 0, 1, or 2).
Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anemia or neutropenia, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue LUTATHERA for Grade 3 or higher anemia or neutropenia requiring a treatment delay of 16 weeks or longer.
Recurrent Grade 3 or 4 Permanently discontinue LUTATHERA.
Renal Toxicity [see Warnings and Precautions (5.4)] Defined as: Creatinine clearance less than 40 mL/min; calculate using Cockcroft Gault with actual body weight, or 40% increase in baseline serum creatinine, or 40% decrease in baseline creatinine clearance; calculate using Cockcroft Gault with actual body weight. Withhold dose until complete resolution.
Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete resolution. If reduced dose does not result in renal toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue LUTATHERA for renal toxicity requiring a treatment delay of 16 weeks or longer.
Recurrent renal toxicity Permanently discontinue LUTATHERA.
Hepatotoxicity [see Warnings and Precautions (5.5)] Defined as: Bilirubinemia greater than 3 times the upper limit of normal (Grade 3 or 4), or Hypoalbuminemia less than 30 g/L with a decreased prothrombin ratio less than 70%. Withhold dose until complete resolution.
Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete resolution. If reduced LUTATHERA dose does not result in hepatotoxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue LUTATHERA for hepatotoxicity requiring a treatment delay of 16 weeks or longer.
Recurrent hepatotoxicity Permanently discontinue LUTATHERA.
Other Non-Hematologic Toxicity Grade 3 or 4 Withhold dose until complete or partial resolution (Grade 0 to 2).
Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue LUTATHERA for Grade 3 or higher toxicity requiring treatment delay of 16 weeks or longer.
Recurrent Grade 3 or 4 Permanently discontinue LUTATHERA.

Administration Instructions

The mean and standard deviation (SD) of the estimated radiation absorbed doses for adults receiving LUTATHERA are shown in Table 3. The maximum penetration in tissue is 2.2 mm and the mean penetration is 0.67 mm.

Table 3. Estimated Radiation Absorbed Dose for LUTATHERA in NETTER-1
Absorbed dose per unit activity (Gy/GBq) (N=20) Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy)
Organ Mean SD Mean SD
Adrenals 0.037 0.016 1.1 0.5
Brain 0.027 0.016 0.8 0.5
Breasts 0.027 0.015 0.8 0.4
Gallbladder Wall 0.042 0.019 1.2 0.6
Heart Wall 0.032 0.015 0.9 0.4
Kidneys 0.654 0.295 19.4 8.7
Liver N=18 (two patients excluded because the liver absorbed dose was biased by the uptake of the liver metastases) 0.299 0.226 8.9 6.7
Lower Large Intestine Wall 0.029 0.016 0.9 0.5
Lungs 0.031 0.015 0.9 0.4
Muscle 0.029 0.015 0.8 0.4
Osteogenic Cells 0.151 0.268 4.5 7.9
Ovaries N=9 (female patients only) 0.031 0.013 0.9 0.4
Pancreas 0.038 0.016 1.1 0.5
Red Marrow 0.035 0.029 1.0 0.8
Skin 0.027 0.015 0.8 0.4
Small Intestine 0.031 0.015 0.9 0.5
Spleen 0.846 0.804 25.1 23.8
Stomach Wall 0.032 0.015 0.9 0.5
Testes N=11 (male patients only) 0.026 0.018 0.8 0.5
Thymus 0.028 0.015 0.8 0.5
Thyroid 0.027 0.016 0.8 0.5
Total Body 0.052 0.027 1.6 0.8
Upper Large Intestine Wall 0.032 0.015 0.9 0.4
Urinary Bladder Wall 0.437 0.176 12.8 5.3
Uterus 0.032 0.013 1.0 0.4

Injection: 370 MBq/mL (10 mCi/mL) of lutetium Lu 177 dotatate as a clear and colorless to slightly yellow solution in a single-dose vial.

None.

LUTATHERA contributes to a patient’s overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices and patient management procedures [see Dosage and Administration ( 2.1)] .

In NETTER-1, myelosuppression occurred more frequently in patients receiving LUTATHERA with long-acting octreotide compared to patients receiving high-dose long-acting octreotide (all grades/grade 3 or 4): anemia (81%/0) versus (54%/1%); thrombocytopenia (53%/1%) versus (17%/0); and neutropenia (26%/3%) versus (11%/0). In NETTER-1, platelet nadir occurred at a median of 5.1 weeks following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the nineteen patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to Grade 1, 9 to Grade 2, and 1 to Grade 3.

Monitor blood cell counts. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction [see Dosage and Administration ( 2.4)] .

In NETTER-1, with a median follow-up time of 24 months, myelodysplastic syndrome (MDS) was reported in 2.7% of patients receiving LUTATHERA with long-acting octreotide compared to no patients receiving high-dose long-acting octreotide. In ERASMUS, 15 patients (1.8%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to the development of MDS was 28 months (9 to 41 months) for MDS and 55 months (32 to 155 months) for acute leukemia.

In ERASMUS, 8 patients (<1%) developed renal failure 3 to 36 months following LUTATHERA. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis.

Administer the recommended amino acid solution before, during and after LUTATHERA [see Dosage and Administration ( 2.3)] to decrease reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Do not decrease the dose of the amino acid solution if the dose of LUTATHERA is reduced. Advise patients to urinate frequently during and after administration of LUTATHERA. Monitor serum creatinine and calculated creatinine clearance. Withhold, reduce dose, or permanently discontinue LUTATHERA based on severity of reaction [see Dosage and Administration ( 2.4)] .

Patients with baseline renal impairment may be at greater risk of toxicity; perform more frequent assessments of renal function in patients with mild or moderate impairment. LUTATHERA has not been studied in patients with severe renal impairment (creatinine clearance < 30 mL/min).

In ERASMUS, 2 patients (<1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure.

Monitor transaminases, bilirubin and serum albumin during treatment. Withhold, reduce dose, or permanently discontinue LUTATHERA based on severity of reaction [see Dosage and Administration ( 2.2)] .

Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm and hypotension, occurred in 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Two (<1%) patients were reported to have hypercalcemia.

Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.

Based on its mechanism of action, LUTATHERA can cause fetal harm [see Clinical Pharmacology ( 12.1)] . There are no available data on the use of LUTATHERA in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including LUTATHERA, have the potential to cause fetal harm.

Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Dosage and Administration ( 2.1)] .

Advise females and males of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose [see Use in Specific Populations ( 8.1, 8.3)] .

LUTATHERA may cause infertility in males and females. The recommended cumulative dose of 29.6 GBq of LUTATHERA results in a radiation absorbed dose to the testis and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see Dosage and Administration ( 2.6) and Use in Specific Populations ( 8.3)] .

The following serious adverse reactions are described elsewhere in the labeling.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in Warnings and Precautions reflect exposure to LUTATHERA in 111 patients with advanced, progressive midgut neuroendocrine tumors (NETTER-1). Safety data in Warnings and Precautions were also obtained in an additional 22 patients in a non-randomized pharmacokinetic substudy of NETTER-1 and in a subset of patients (811 of 1214) with advanced somatostatin receptor-positive tumors enrolled in ERASMUS [see Warnings and Precautions ( 5)] .

NETTER-1 The safety data described below are from NETTER-1, which randomized (1:1) patients with progressive, somatostatin receptor-positive midgut carcinoid tumors to receive LUTATHERA 7.4 GBq (200 mCi) administered every 8 to 16 weeks concurrently with the recommended amino acid solution and with long-acting octreotide (30 mg administered by intramuscular injection within 24 hours of each LUTATHERA dose) (n = 111), or high-dose octreotide (defined as long-acting octreotide 60 mg by intramuscular injection every 4 weeks) (n = 112) [see Clinical Studies ( 14.1)] . Among patients receiving LUTATHERA with octreotide, 79% received a cumulative dose > 22.2 GBq (> 600 mCi) and 76% of patients received all four planned doses. Six percent (6%) of patients required a dose reduction and 13% of patients discontinued LUTATHERA. Five patients discontinued LUTATHERA for renal-related events and 4 discontinued for hematological toxicities. The median duration of follow-up was 24 months for patients receiving LUTATHERA with octreotide and 20 months for patients receiving high-dose octreotide.

Table 4 and Table 5 summarize the incidence of adverse reactions and laboratory abnormalities, respectively. The most common Grade 3-4 adverse reactions occurring with a greater frequency among patients receiving LUTATHERA with octreotide compared to patients receiving high-dose octreotide include: lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea and elevated AST (5% each), and increased ALT, hyperglycemia and hypokalemia (4% each).

ERASMUS Safety data are available from 1214 patients in ERASMUS, an international, single-institution, single-arm, open-label trial of patients with somatostatin receptor-positive tumors (neuroendocrine and other primaries). Patients received LUTATHERA 7.4 GBq (200 mCi) administered every 6 to 13 weeks with or without octreotide. Retrospective medical record review was conducted on a subset of 811 patients to document serious adverse reactions. Eighty-one (81%) percent of patients in the subset received a cumulative dose ≥ 22.2 GBq (≥ 600 mCi). With a median follow-up time of more than 4 years, the following rates of serious adverse reactions were reported: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%).

Table 4. Adverse Reactions Occurring in ≥ 5% (All Grades) of Patients Receiving LUTATHERA with Octreotide in NETTER-1
Adverse Reaction National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays adverse reactions occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥5% (all grades) or ≥2% (grades 3-4)] LUTATHERA and Long-Acting Octreotide (30 mg)  (N = 111) Long-Acting Octreotide (60 mg) (N = 112)
All Grades % Grades 3-4 % All Grades % Grades 3-4 %
Cardiac disorders
Atrial fibrillation 5 1 0 0
Gastrointestinal disorders
Nausea 65 5 12 2
Vomiting 53 7 9 0
Abdominal pain 26 3 19 3
Diarrhea 26 3 18 1
Constipation 10 0 5 0
General disorders
Fatigue 38 1 26 2
Peripheral edema 16 0 9 1
Pyrexia 8 0 3 0
Metabolism and nutrition disorders
Decreased appetite 21 0 11 3
Musculoskeletal and connective tissue disorders
Back pain 13 2 10 0
Pain in extremity 11 0 5 0
Myalgia 5 0 0 0
Neck Pain 5 0 0 0
Nervous system disorders
Headache 17 0 5 0
Dizziness 17 0 8 0
Dysgeusia 8 0 2 0
Psychiatric disorders
Anxiety 12 1 5 0
Renal and urinary disorders
Renal failure Includes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotemia, renal disorder, renal failure, renal impairment 12 3 3 1
Radiation-related urinary tract toxicity Includes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence 8 0 3 0
Respiratory, thoracic and mediastinal disorders
Cough 11 1 6 0
Skin and subcutaneous tissue disorders
Alopecia 12 0 2 0
Vascular disorders
Flushing 14 1 9 0
Hypertension 12 2 7 2
Table 5. Laboratory Abnormalities Occurring in ≥ 5% (All Grades) of Patients Receiving LUTATHERA with Octreotide in NETTER-1 Values are worst grade observed after randomization
Laboratory Abnormality National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays laboratory abnormalities occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥5% (all grades) or ≥2%(grades 3-4)] LUTATHERA and Long-Acting Octreotide (30 mg)  (N = 111) Long-Acting Octreotide (60 mg)
(N = 112)
All grades % Grade 3-4 % All grades % Grade 3-4 %
Hematology
Lymphopenia 90 44 39 4
Anemia 81 0 54 1
Leukopenia 55 2 20 0
Thrombocytopenia 53 1 17 0
Neutropenia 26 3 11 0
Renal/Metabolic
Creatinine increased 85 1 73 0
Hyperglycemia 82 4 67 2
Hyperuricemia 34 6 29 6
Hypocalcemia 32 0 14 0
Hypokalemia 26 4 21 2
Hyperkalemia 19 0 11 0
Hypernatremia 17 0 7 0
Hypoglycemia 15 0 8 0
Hepatic
GGT increased 66 20 67 16
Alkaline phosphatase increased 65 5 54 9
AST increased 50 5 35 0
ALT increased 43 4 34 0
Blood bilirubin increased 30 2 28 0

Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended [see Dosage and Administration ( 2.3)] .

Risk Summary Based on its mechanism of action, LUTATHERA can cause fetal harm [see Clinical Pharmacology ( 12.1)] . There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including LUTATHERA, have the potential to cause fetal harm. Advise pregnant women of the risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Risk Summary There are no data on the presence of lutetium Lu 177 dotatate in human milk, or its effects on the breastfed infant or milk production. No lactation studies in animals were conducted. Because of the potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the final dose.

Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Use in Specific Populations ( 8.1)] .

Contraception Females LUTATHERA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1)] . Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the final dose of LUTATHERA.

Males Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during and for 4 months following the final dose of LUTATHERA [see Clinical Pharmacology ( 12.1) and Nonclinical Toxicology ( 13.1)] .

Infertility The recommended cumulative dose of 29.6 GBq of LUTATHERA results in a radiation absorbed dose to the testis and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see Dosage and Administration ( 2.6)] .

The safety and effectiveness of LUTATHERA have not been established in pediatric patients.

Of the 1325 patients treated with LUTATHERA in clinical trials, 438 patients (33%) were 65 years and older. The response rate and number of patients with a serious adverse event were similar to that of younger subjects.

No dose adjustment is recommended for patients with mild to moderate renal impairment; however, patients with mild or moderate renal impairment may be at greater risk of toxicity. Perform more frequent assessments of renal function in patients with mild to moderate impairment. The safety of LUTATHERA in patients with severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault) or end-stage renal disease has not been studied.

No dose adjustment is recommended for patients with mild or moderate hepatic impairment. The safety of LUTATHERA in patients with severe hepatic impairment (total bilirubin > 3 times upper limit of normal and any AST) has not been studied.

LUTATHERA (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog. The drug substance lutetium Lu 177 dotatate is a cyclic peptide linked with the covalently bound chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to a radionuclide.

Lutetium Lu 177 dotatate is described as lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic (2-7) disulfide. The molecular weight is 1609.6 Daltons and the structural formula is as follows:

LUTATHERA (lutetium Lu 177 dotatate) 370 MBq/mL (10 mCi/mL) Injection is a sterile, clear, colorless to slightly yellow solution for intravenous use. Each single-dose vial contains acetic acid (0.48 mg/mL), sodium acetate (0.66 mg/mL), gentisic acid (0.63 mg/mL), sodium hydroxide (0.65 mg/mL), ascorbic acid (2.8 mg/mL), diethylene triamine pentaacetic acid (0.05 mg/mL), sodium chloride (6.85 mg/mL), and Water for Injection (ad 1 mL). The pH range of the solution is 4.5 to 6.

Lutetium (Lu 177) decays to stable hafnium (Hf 177) with a half-life of 6.647 days, by emitting beta radiation with a maximum energy of 0.498 MeV and photonic radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.4%). The main radiations are detailed in Table 6.

Table 6. Lu 177 Main Radiations
Radiation Energy (keV) Iβ% Iγ%
β - 176.5 12.2
β - 248.1 0.05
β - 384.9 9.1
β - 497.8 78.6
γ 71.6 0.15
γ 112.9 6.40
γ 136.7 0.05
γ 208.4 11.0
γ 249.7 0.21
γ 321.3 0.22

Table 7 summarizes the radioactive decay properties of Lu 177.

Table 7. Physical Decay Chart: Lutetium Lu 177 Half-life = 6.647 days
Hours Fraction Remaining Hours Fraction Remaining
0 1.000 48 (2 days) 0.812
1 0.996 72 (3 days) 0.731
2 0.991 168 (7 days) 0.482
5 0.979 336 (14 days) 0.232
10 0.958 720 (30 days) 0.044
24 (1 day) 0.901 1080 (45 days) 0.009

Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.

Lutetium Lu 177 exposure-response relationships and the time course of pharmacodynamics response are unknown.

Cardiac Electrophysiology The ability of LUTATHERA to prolong the QTc interval at the therapeutic dose was assessed in an open label study in 20 patients with somatostatin receptor-positive midgut carcinoid tumors. No large changes in the mean QTc interval (i.e., >20 ms) were detected.

The pharmacokinetics (PK) of lutetium Lu 177 dotatate have been characterized in patients with progressive, somatostatin receptor-positive neuroendocrine tumors. The mean blood exposure (AUC) of lutetium Lu 177 dotatate at the recommended dose is 41 ng.h/mL [coefficient of variation (CV) 36 %]. The mean maximum blood concentration (C ) for lutetium Lu 177 dotatate is 10 ng/mL (CV 50%), which generally occurred at the end of the LUTATHERA infusion.

Distribution The mean volume of distribution for lutetium Lu 177 dotatate is 460 L (CV 54%).

Within 4 hours after administration, lutetium Lu 177 dotatate distributes in kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid. The co-administration of amino acids reduced the median radiation dose to the kidneys by 47% (34% to 59%) and increased the mean beta-phase blood clearance of lutetium Lu 177 dotatate by 36%.

The non-radioactive form of lutetium dotatate is 43% bound to human plasma proteins.

Elimination The mean clearance (CL) is 4.5 L/h (CV 31%) for lutetium Lu 177 dotatate. The mean (± standard deviation) effective blood elimination half-life is 3.5 (±1.4) hours and the mean terminal blood half-life is 71 (± 28) hours.

Metabolism Lutetium Lu 177 dotatate does not undergo hepatic metabolism.

Excretion Lutetium Lu 177 dotatate is primarily eliminated renally with cumulative excretion of 44% within 5 hours, 58% within 24 hours, and 65% within 48 hours following LUTATHERA administration. Prolonged elimination of lutetium Lu 177 dotatate in the urine is expected; however, based on the half-life of lutetium 177 and terminal half-life of lutetium Lu 177 dotatate, greater than 99% will be eliminated within 14 days after administration of LUTATHERA [see Warnings and Precautions ( 5.1)] .

Drug Interaction Studies The non-radioactive form of lutetium is not an inhibitor or inducer of cytochrome P450 (CYP) 1A2, 2B6, 2C9, 2C19 or 2D6 in vitro. It is not an inhibitor of P-glycoprotein, BCRP, OAT1, OAT3, OCT2, OATP1B1, OATP1B3, or OCT1 in vitro.

Carcinogenicity and mutagenicity studies have not been conducted with Lutetium Lu 177 dotatate; however, radiation is a carcinogen and mutagen.

No animal studies were conducted to determine the effects of lutetium Lu 177 dotatate on fertility.

The primary target organ in animal studies using a non-radioactive form of lutetium Lu 177 dotatate (lutetium Lu 175 dotatate) was the pancreas, a high SSTR2 expressing organ. Pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses ≥ 5 mg/kg in repeat dose toxicology studies in rats. Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses ≥ 500 mg/kg. These findings were consistent with high uptake of the radiolabeled peptide in the pancreas in animal biodistribution studies.

The efficacy of LUTATHERA in patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumors was established in NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial. Key eligibility criteria included Ki67 index ≤ 20%, Karnofsky performance status ≥ 60, confirmed presence of somatostatin receptors on all lesions (OctreoScan uptake ≥ normal liver), creatinine clearance ≥ 50 mL/min, no prior treatment with peptide receptor radionuclide therapy (PRRT), and no prior external radiation therapy to more than 25% of the bone marrow.

Two hundred twenty-nine (229) patients were randomized (1:1) to receive either LUTATHERA 7.4 GBq (200 mCi) every 8 weeks for up to 4 administrations (maximum cumulative dose of 29.6 GBq) or high-dose long-acting octreotide (defined as 60 mg by intramuscular injection every 4 weeks). Patients in the LUTATHERA arm also received long-acting octreotide 30 mg as an intramuscular injection 4 to 24 hours after each LUTATHERA dose and every 4 weeks after completion of LUTATHERA treatment until disease progression or until week 76 of the study. Patients in both arms could receive short-acting octreotide for symptom management; however, short-acting octreotide was withheld for at least 24 hours before each LUTATHERA dose. Randomization was stratified by OctreoScan tumor uptake score (Grade 2, 3 or 4) and the length of time that patients had been on the most recent constant dose of octreotide prior to randomization (≤ 6 or > 6 months). The major efficacy outcome measure was progression free survival (PFS) as determined by a blinded independent radiology committee (IRC) per RECIST v1.1. Additional efficacy outcome measures were overall response rate (ORR) by IRC, duration of response, and overall survival (OS).

Demographic and baseline disease characteristics were balanced between the treatment arms. Of the 208 patients, whose race/ethnicity was reported, 90% were White, 5% were Black, and 4% were Hispanic or Latino. The median age was 64 years (28 to 87 years); 51% were male, 74% had an illial primary, and 96% had metastatic disease in the liver. The median Karnofsky performance score was 90 (60 to 100), 74% received a constant dose of octreotide for > 6 months and 12% received prior treatment with everolimus. Sixty-nine percent of patients had Ki67 expression in ≤ 2% of tumor cells, 77% had CgA > 2 times the upper limit of normal (ULN), 65% had 5-HIAA > 2 x ULN, and 65% had alkaline phosphatase ≤ ULN. Efficacy results for NETTER-1 are presented in Table 8 and Figure 1.

NR: Not reached; NE: Not evaluable

Table 8. Efficacy Results in NETTER-1
LUTATHERA and Long-Acting Octreotide (30 mg)
N=116
Long-Acting Octreotide (60 mg)
N=113
PFS by IRC
   Events (%) 27 (23%) 78 (69%)
      Progressive disease, n (%) 15 (13%) 61 (54%)
      Death, n (%) 12 (10%) 17 (15%)
   Median in months (95% CI) NR Median follow-up 10.5 months at time of primary analysis of PFS (range: 0 to 29 months) (NE, NE) 8.5 (5.8, 9.1)
   Hazard ratio Hazard ratio based on the unstratified Cox model (95% CI) 0.21 (0.13, 0.32)
   P-Value Unstratified log rank test < 0.0001
OS (Updated)
   Deaths (%) 27 (23%) 43 (38%)
   Median in months (95% CI) NR (31.0, NE) 27.4 (22.2, NE)
   Hazard ratio Interim analysis of OS not statistically significant based on pre-specified significance criteria (95% CI) 0.52 (0.32, 0.84)
ORR by IRC
   ORR, % (95% CI) 13% (7%,19%) 4% (0.1%, 7%)
      Complete response rate, n (%) 1 (1%) 0
      Partial response rate, n (%) 14 (12%) 4 (4%)
   P-Value Fisher’s Exact test 0.0148
   Duration of response, median in months (95% CI) NR (2.8, NE) 1.9 (1.9, NE)

The efficacy of LUTATHERA in patients with foregut, midgut, and hindgut gastroenteropancreatic neuroendocrine tumors (GEP-NETs) was assessed in 360 patients in the ERASMUS study. In ERASMUS, LUTATHERA was initially provided as expanded access under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. A subsequent LUTATHERA-specific protocol written eight years after study initiation did not describe a specific sample size or hypothesis testing plan but allowed for retrospective data collection. A total of 1214 patients received LUTATHERA in ERASMUS, of which 601 (50%) were assessed per RECIST criteria. Of the 601 patients evaluated by investigators using RECIST criteria, 360 (60%) had gastroentero-pancreatic neuroendocrine tumors (GEP-NETs). LUTATHERA 7.4 GBq (200 mCi) was administered every 6 to 13 weeks for up to 4 doses concurrently with the recommended amino acid solution. The major efficacy outcome was investigator-assessed ORR. The median age in the efficacy subset was 61 years (25 to 88 years), 52% were male, 61% had a baseline Karnofsky performance status ≥ 90 (60 to 100), 60% had progressed within 12 months of treatment, and 15% had received prior chemotherapy. Fifty five percent (55%) of patients received a concomitant somatostatin analog. The median dose of LUTATHERA was 29.6 GBq (800 mCi). Baseline tumor assessments were obtained in 39% of patients. The investigator assessed ORR was 16% (95% CI 13, 20) in the 360 patients with GEP-NETs. Three complete responses were observed (< 1%). Median DoR in the 58 responding patients was 35 months (95% CI: 17, 38).

LUTATHERA Injection containing 370 MBq/mL (10 mCi/ml) of lutetium Lu 177 dotatate is a sterile, preservative-free and clear, colorless to slightly yellow solution for intravenous use supplied in a colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 dotatate at the time of injection ( NDC# 69488-003-01). The solution volume in the vial is adjusted from 20.5 mL to 25 mL to provide a total of 7.4 GBq (200 mCi) of radioactivity.

The product vial is in a lead shielded container placed in a plastic sealed container ( NDC# 69488-003-01). The product is shipped in a Type A package ( NDC# 69488-003-70).

Store below 25 °C (77 °F).

The shelf life is 72 hours. Discard appropriately at 72 hours.

Radiation Risks Advise patients to minimize radiation exposure to household contacts consistent with institutional good radiation safety practices and patient management procedures [see Dosage and Administration ( 2.1), Warnings and Precautions ( 5.1)] .

Myelosuppression Advise patients to contact their healthcare provider for any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, or increased bleeding or bruising [see Warnings and Precautions ( 5.2)] .

Secondary Myelodysplastic Syndrome and Acute Leukemia Advise patients of the potential for secondary cancers, including myelodysplastic syndrome and acute leukemia [see Warnings and Precautions ( 5.3)] .

Renal Toxicity Advise patients to hydrate and urinate frequently during and after administration of LUTATHERA [see Warnings and Precautions ( 5.4)] .

Hepatotoxicity Advise patients of the need for periodic laboratory tests to monitor for hepatotoxicity [see Warnings and Precautions ( 5.5)] .

Neuroendocrine Hormonal Crises Advise patients to contact their health care provider for signs or symptoms that may occur following tumor-hormone release, including severe flushing, diarrhea, bronchospasm, and hypotension [see Warnings and Precautions ( 5.6)] .

Embryo-Fetal Toxicity Advise pregnant women and males and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.7), Use in Specific Populations ( 8.1, 8.3)] .

Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the final dose [see Use in Specific Populations ( 8.1, 8.3)] .

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LUTATHERA and for 4 months after the final dose [see Use in Specific Populations ( 8.1, 8.3)] .

Lactation Advise females not to breastfeed during treatment with LUTATHERA and for 2.5 months after the final dose [see Use in Specific Populations ( 8.2)] .

Infertility Advise female and male patients that LUTATHERA may impair fertility [see Warnings and Precautions ( 5.8), Use in Specific Populations ( 8.3)] .

Manufactured by: Advanced Accelerator Applications, S.r.l. Via Ribes 5, 10010 Colleretto Giacosa (TO), Italy

Advanced Accelerator Applications, S.r.l. Via Piero Maroncelli 40/1, 47014 Meldola (FC), Italy

Or

Advanced Accelerator Applications USA, Inc. 57 East Willow Street, Millburn, NJ 07041, USA

Distributed by: Advanced Accelerator Applications USA, Inc., NJ 07041

© Advanced Accelerator Applications USA, Inc. 2018 LUTATHERA® is a registered trademark of Advanced Accelerator Applications S.A.

U.S. Patents 5830431; 5804157

Vial Label: 2.97 cm x 7 cm

Secondary Packaging (Lead Shielding): 5.7 cm x 10.5 cm

Type A Label (ADR): 14.85 cm x 21 cm

Type A Label (IATA): 14.85 cm x 21 cm

Manufacturer

Advanced Accelerator Applications USA, Inc

Active Ingredients

Source

Drugs and Medications [0 Results]

None

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Post-Authorization Long-Term Safety Study of LUTATHERA

Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

This research study is being done to assess the safety and tolerability of study drugs, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) and nivolumab in subjects with small cell lung cancer or adv...

Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy

Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has b...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record